C. Kilday

Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia.

C. Packard, J. Shepherd, A. Lorimer, 1990, British journal of clinical pharmacology.

Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study.

P. Macfarlane, J. Kennedy, J. Norrie, 1997, European heart journal.

Influence of etofibrate on low density lipoprotein metabolism.

C. Packard, M. Caslake, J. Shepherd, 1988, Atherosclerosis.

Relationship of Interferon-γ to Cognitive Function in Midlife Women with Schizophrenia

D. Kelly, H. Wehring, L. Rubin, 2018, Psychiatric Quarterly.

Effect of combined therapy with bezafibrate and cholestyramine on low-density lipoprotein metabolism in type IIa hypercholesterolemia.

C. Packard, M. Caslake, J. Shepherd, 1989, Metabolism: clinical and experimental.

Increased circulating regulatory T cells in medicated people with schizophrenia

D. Kelly, S. Feldman, R. Buchanan, 2018, Psychiatry Research.

West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials

P. Macfarlane, J. Kennedy, J. Norrie, 1996 .